{"nctId":"NCT05111145","briefTitle":"A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)","startDateStruct":{"date":"2022-01-14","type":"ACTUAL"},"conditions":["Cystic Fibrosis"],"count":86,"armGroups":[{"label":"ELX/TEZ/IVA","type":"EXPERIMENTAL","interventionNames":["Drug: ELX/TEZ/IVA","Drug: IVA"]}],"interventions":[{"name":"ELX/TEZ/IVA","otherNames":["VX-445/VX-661/VX-770","elexacaftor/tezacaftor/ivacaftor"]},{"name":"IVA","otherNames":["VX-770","ivacaftor"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Completed study drug treatment in parent study (VX19-445-117 \\[NCT04599465\\] or VX20-445-126 \\[NCT04969224\\]), or had study drug interruption(s) in parent study but completed study visits up to the last scheduled visit of the treatment period in the parent study\n\nKey Exclusion Criteria:\n\n* History of drug intolerance in a parent study\n\nOther protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":86},"commonTop":["COVID-19","Infective pulmonary exacerbation of cystic fibrosis","Nasopharyngitis","Upper respiratory tract infection"]}}}